[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100389720":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":23,"locations":34,"responsibleParty":52,"collaborators":56,"id":60,"slug":10,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":10,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of California, Los Angeles","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1",null,"Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks",[13],"Drug: Xiidra (Lifitegrast ophthalmic solution) 5%",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Xiidra (Lifitegrast ophthalmic solution) 5%","FDA approved lifitegrast opthalmic solution eye drop",[9],[21,22],"Lifitegrast ophthalmic solution","SAR-1118",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Benjamin B Bert, MD","CONTACT","626-817-4701","BBert@mednet.ucla.edu",{"name":30,"role":26,"phone":31,"phoneExt":32,"email":33},"Mayra Raygoza","16268174747","19093","Mraygoza@mednet.ucla.edu",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Doheny Eye Center UCLA","RECRUITING","Fountain Valley","California","92708","United States",{"type":43,"coordinates":44},"Point",[45,46],-117.95367,33.70918,{"lat":46,"lon":45},[49],{"name":25,"role":26,"phone":50,"phoneExt":10,"email":51},"7149631444","JanettMendez@mednet.ucla.edu",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Benjamin B. Bert, MD","Health Sciences Assistant Professor",[57],{"name":58,"class":59},"Bausch & Lomb Incorporated","INDUSTRY","100389720",false,"NCT04354545","Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications","Inclusion Criteria:\n\n* Currently using one or more topical glaucoma antihypertensives\n* Self-described symptoms of ocular surface discomfort\n* Xiidra is being prescribed as part of the subject's standard care\n\nExclusion Criteria:\n\n* History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),\n* current use of topical cyclosporine\n* current use of topical steroids\n* incisional ocular surgery within 6 months",true,"ALL",{"count":68,"type":69},75,"ESTIMATED","OBSERVATIONAL","To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.",[73,74],"Glaucoma","Ocular Surface Disease",[76,77,78],"glaucoma","xiidra™","ocular surface discomfort","2026-03-11",{"date":81,"type":82},"2026-03-13","ACTUAL",{"date":84,"type":82},"2021-04-01",{"date":86,"type":69},"2026-12-01",{"name":5,"class":6},1]